Binds the vesicular monoamine transporter (VMAT2) and inhibits transport of biogenic amines into adrenal chromaffin granules and synaptic vesicles. Causes depletion of biogenic amine stores. Antihypertensive and antipsychotic.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 608.68. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||16.43 mL||82.14 mL||164.29 mL|
|0.5 mM||3.29 mL||16.43 mL||32.86 mL|
|1 mM||1.64 mL||8.21 mL||16.43 mL|
|5 mM||0.33 mL||1.64 mL||3.29 mL|
References are publications that support the biological activity of the product.
Schuldiner et al (1993) Reserpine binding to a vesicular amine transporter expressed in chinese hamster ovary fibroblasts. J.Biol.Chem. 268 29 PMID: 8416935
Heslop and Curzon (1999) Effect of reserpine on behavioural responses to agonists at 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT2C receptor subtypes. Neuropharmacology 38 883 PMID: 10465692
Metzger et al (2002) Inhibitory effect of reserpine on DA transporter function. Eur.J.Pharmacol. 456 39 PMID: 12450567
If you know of a relevant reference for Reserpine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Reserpine, Reserpine supplier, inhibitors, inhibits, vesicular, monoamine, transporters, Noradrenalin, NET, Adrenergic, Transporters, Monoamine, Neurotransmitter, DAT, Dopamine, Serotonin, SERT, 5-HT, reuptake, 5-Hydroxytryptamine, VMAT2, noradrenaline, Vesicular, 2742, Tocris Bioscience
4 Citations for Reserpine
Citations are publications that use Tocris products. Selected citations for Reserpine include:
Berrios et al (2016) Loss of UBE3A from TH-expressing neurons suppresses GABA co-release and enhances VTA-NAc optical self-stimulation. Neuropsychopharmacology 7 10702 PMID: 26869263
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. J Immunol 40 766 PMID: 25249058
Prado et al (2012) Stimulation of DA receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. Cell Tissue Res 188 3062 PMID: 22379034
Njagi et al (2010) Electrochemical quantification of serotonin in the live embryonic zebrafish intestine. Anal Chem 82 1822 PMID: 20148518
Do you know of a great paper that uses Reserpine from Tocris? Please let us know.
Reviews for Reserpine
Average Rating: 5 (Based on 1 Review.)
Have you used Reserpine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
This product work super fine in electrophysiology for blocking the VMAT. We currently use it at the concentration of 5 µM in normal ACSF.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.